Description
This technology is a series of innovative RSV reporter tools for high throughput screening of anti-viral drug candidates. Our reporter tools offer innovative solutions for RSV drug discovery and vaccine development, with improved sensitivity and robustness compared to conventional fluorescent assays. Additionally, these tools are simplified, shortened versions of the viral genome, allowing safer RSV research in lower BSL environments.
RSV is a leading cause of respiratory infections in infants, young children, and elderly worldwide. In the U.S. alone, there are 60,000–160,000 hospitalizations in adults over 65 years old each year. Due to the limited duration of effect, high cost, and suboptimal anti-inflammatory properties of existing RSV vaccines, there is a pressing need to further develop enhanced RSV vaccines.
Benefits
- Safer: Does not require high-level biosafety containment facilities.
- Improved Sensitivity: High sensitivity compared to conventional fluorescent assays, allowing detection of low concentrations of RSV virus in samples
- High-Throughput Screening: Can be used in high throughput screening for RSV vaccine and drugs, allowing processing of large numbers of samples with reduced cost and lab labor per sample
- Quantification of Viral Activity: Enables precise quantification of viral activity
Applications
- RSV Research and development
- RSV anti-viral drug discovery
- RSV vaccine development
Patent Status
Publications
A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis - ScienceDirect
Dual Myxovirus Screen Identifies a Small-Molecule Agonist of the Host Antiviral Response | Journal of Virology
4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication - PubMed (nih.gov)
Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase - PubMed (nih.gov)
